Introduction of a thrombin sensor based on its interaction with dabigatran as an oral direct thrombin inhibitor

Paimard, Giti; Gholivand, Mohammad Bagher; Shamsipur, Mojtaba; Ahmadi, Elham; Shahlaei, Mohsen

doi:10.1016/j.msec.2020.111417

Cited by 10 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection of thrombin catalytic activity in ten-fold diluted serum has been reported previously [ 31 ]. Consequently, the same dilution will be used in this work to quantify DAB using the thrombin-based sensor.…”

Section: Resultsmentioning

confidence: 99%

Electrochemical Disposable Biosensor to Monitor Dabigatran in Point-of-Care Anticoagulation Therapy

2023

View full text Add to dashboard Cite

Dabigatran etexilate, an oral prodrug, is often used to treat complications linked to thrombosis. Dabigatran (DAB, active form) does not need to be monitored. However, there are several conditions, such as reduced renal function, traumatic bleeding, emergency surgery, the need for thrombolytic therapy in acute stroke, or the requirement to use other forms of anticoagulation, where knowing the concentration of DAB in the blood is indispensable. Unfortunately, there are no convenient DAB-specific point-of-care tests available. To solve this problem, two disposable sensors were constructed and optimised in this work to detect the anticoagulant drug DAB using novel co-facing disposable electrodes, which allows a calibration-free quantitation of the electroactive mediator concentration. A trypsin-based sensor was evaluated. This sensor performed well in a 10 mM Tris buffer (pH 8.8) solution. However, trypsin was inhibited by alpha-1 antitrypsin when a plasma sample was introduced into the sensor. This problem was overcome by plasma filtration. This sensor showed a detection limit of 50.7 ng mL−1 DAB in plasma and a quantification range of 177–500 ng mL−1. A thrombin-based sensor was also constructed. This sensor performed well in ten-fold diluted plasma, overcoming the filtration problem observed with the trypsin-based sensor. This sensor showed a detection limit of 9.6 ng mL−1 DAB in plasma and a quantification range of 11.5–140 ng mL−1. Its extensive pH stability range, the possibility of working at physiological pH, low volume, low cost, and fast turnaround response (less than 20 s) make the calibration-free thrombin-based sensor a suitable point-of-care test to measure DAB concentration in the blood.

show abstract

Section: Resultsmentioning

confidence: 99%